Aclerastide is being investigated for the treatment of diabetic wound healing, and more specifically for diabetic foot ulcers (DFU). It failed Phase III clinical trials in November 2015 for treatment of DFU, where it was applied daily for several weeks. Aclerastide, also known as DSC-127, and NorLeu3-A(1-7), is a potent peptide analog of angiotensin II, a growth factor that plays an important role in dermal repair and wound healing by promoting angiogenesis, producing reactive oxygen species, and inducing migration of fibroblasts and keratinocytes. In animal models, aclerastide showed more rapid deposition of collagen, acceleration of epithelial growth, altered leukocyte infiltration, and increased blood vessel formation.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Aclerastide, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.